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Gabriel Crane astutely describes the placebo effect as physiological and psychological responses that can mitigate signs and 
symptoms of several types of disorders, and more 
generally, perhaps produce salutory effects (Crane, 
2016). Crane rightly notes that placebo effects have 
been somewhat enigmatic to both research and medical 
practice(s), in part because of inappropriate and/or 
insufficient theoretical orientations to the nature of such 
responses and effects.  In many ways, this reflects the 
mechanistic conundrum common to much of Western 
science and medicine: we do not accept that something 
may or can be effective unless we can demonstrate a 
viable mechanism for such effects (Giordano, 2010). 
Indubitably, mechanistic understanding is important to 
define substrates involved, the potential for these to be 
elicited in particular individuals, and if and how such 
processes might incur various beneficial/desirable or 
deleterious effects.  
 As Crane has shown, ongoing studies by a 
number of groups have been important to elucidating 
such mechanisms, and in this way, may have provided 
a proverbial “check in the block” toward fortifying 
mechanism-to-effect considerations that could 
substantiate the viability of use-in-practice (Crane, 
2016).  Given the substance and findings of this work, 
Karen Rommelfanger (2013), like Crane, has queried 
whether we are harming patients by withholding placebo 
treatment.  In attempting to posit an answer I herein 
offer that it is – and will be increasingly – important 
to contextualize putative mechanisms and empirically 
observed effects of placebo to the act of medicine and 
clinical encounter. This approach can serve to fortify 
a deepened understanding of if, why and how placebo 
responses – and the events that evoke them - may be 
valid and of value, and how these can and perhaps 
should be utilized in clinical practice. 
Putative Mechanisms 
of Placebo Response(s)
As Crane has reported, several neural loci and networks are likely engaged in and by placebo 
responses. Brainstem systems engage sensory input 
from a variety of stimuli from the external and internal 
environment to attend to feature orientation and 
attendance.  Differential activation of reticulo-thalamic 
neuraxes involved in attention, emotion and ‘directed’ 
consciousness (i.e.- ‘consciousness of ’ a circumstance 
and the attendant emotional ‘valence’) can create a basal 
emotional state that, when taken together with activation 
of networks involving the amygdala, insula and regions 
of the associative, cingulate, temporal and parietal 
cortices,  fosters a sense of ‘intentionality’. Concomitant 
and/or subsequent engagement of hippocampal, and 
parahippocampal cortical neuraxes conjoin working 
and declarative memory to frame experience within past 
and current circumstance(s). Networks of right and/
or left prefrontal and orbitofrontal cortices participate, 
at least to some extent, in higher order expectational 
or anticipatory cognitions to afford objectification and 
intentionality to situational experience, and relate such 
experience to prior, current or potential circumstances. 
(Benedetti, Mayberg, Wager, et al, 2005; Kohls, Sauer, 
Offenbächer, & Giordano, 2011)
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 These mechanisms appear to function in 
hierarchical processing. During initial stages of placebo 
response, frontal and prefrontal cortices (that contribute 
to network processing of expectation), activate the 
periaqueductal grey region (PAG) and decrease activity 
of the anterior insula, thalamus, and anterior cingulate 
gyrus, to evoke direct sensory, rather than perceptual 
modulation of physiological input. Late(r) stage placebo 
responses involve reduced activity of the anterior and 
medial cingulate gyrus and amygdala, and support that 
progressive and relatively durable placebo responses 
reflect the involvement of other brain loci and networks 
(Benedetti, Mayberg, Wager, et al., 2005).
Fitting “Treatment” to the “Disorder”: 
Research to Indicate “Right Use”
An understanding of these mechanisms is important when attempting to meet the clinical adage of the 
“right treatment for the right diagnosis”. In this light, 
ongoing research will be crucial to determining what 
works (and what doesn’t), in whom, when, under which 
conditions, and what mechanisms are involved. Such 
studies can define how psychophysiological variables incur 
patient responses and therapeutic outcomes as influential 
and applicable, albeit with caveat, to the conduct of the 
clinical encounter. Reflecting the Sydenhamian tradition, 
the key elements of the clinical encounter are the 
determination of 1) what is wrong with the patient, 2) what 
can be done (given knowledge of and about the disorder 
as expressed in/by the specific patient and the range of 
potential interventions that target mechanisms and effects 
of the disorder); and from these variables 3) what should 
be done. But here it is necessary to recognize the multi-
dimensional nature of “good” relevant to not only what 
is biomedically sound, but if and how the application or 
engagement of biomedical factors affect an individual 
patient’s nature and predicament of illness, circumstances, 
values, and choices (Pellegrino and Thomasma, 1993). So, 
for those disorders that have been shown to involve neural 
substrates that have been demonstrated to be affected in 
and by placebo responses, evoking placebo may aptly align 
the treatment with the disorder (Giordano 2007).
Practical and Ethical Issues: 
Toward “Good Use”
It is from this perspective that I concur with Crane and urge re-examination of the concept – and use - of 
placebo. While used in the research literature to refer 
to a sham treatment, I offer a more accurate definition 
of placebo responses to be those processes that induce 
neuropsychological effects that are facilitative to 
healing, and which I believe, like Crane, can – and 
should -  be more validly considered for therapeutic 
value in light of current neuroscientific information and 
understanding. But any such consideration should not 
be cavalier; adherence to clinical equipoise dictates that 
like any potential treatment approach, the use of placebo 
responses must be weighed against other possible 
and viable interventions in light of available evidence, 
particulars of the case, and the relative balancing of 
benefits, burdens, risks and harms (Giordano, 2008). 
Simply put, knowing that a particular treatment can 
evoke mechanisms to produce positive outcomes does 
not explicitly compel or sustain that it should be used. 
 Additionally, while placebo responses and 
effect(s) may be viewed as valid means to mitigate the 
signs and symptoms of certain types of  disorders, I 
believe, pro philosopher Sisela Bok, that achieving these 
means by blatantly lying incurs ethical harms through: 
1) intentional deception, 2)  undermining the veracity 
that establishes and maintains trust within the physician-
patient relationship, 3) denying patients information 
necessary for valid informed consent, and 4) impugning 
patients’ autonomy, in this sense, the negative right to 
refuse particular treatments (Bok, 1974; see also: Gillon, 
1985; and Bloche, 2000).  This impels consideration of if 
and how placebo responses might be ethically achieved 
and used in clinical practice. 
 Disclosing that a certain intervention may 
induce placebo responses does not necessarily reduce 
the potential for effects, particularly if and when 
circumstances in which this information is provided 
afford sufficiently positive reinforcement for patients' 
expectations of the clinical encounter (Colloca and 
Benedetti, 2005; Geers et al. 2005).  A physician 
could assert that a particular intervention may engage 
mechanisms that, in some ways, can reduce feelings 
of illness and perhaps evoke physiological recuperative 
processes, and that the actual mechanisms of this effect 
are not fully known. To be sure, despite myriad advances 
in bioscience and technology, in many ways medicine still 
remains a relatively uncertain practice. Communicating 
this uncertainty to patients with a sense of optimism 
allows for veracity and intellectual honesty, while still 
fostering trust and hope (Giordano and Boswell, 2005; 
Geers et al., 2005; Spiro, 1986). 
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 Ethico-legal questions also center upon the 
cost of interventions that are used to evoke placebo 
responses (Bok, 1974). Namely, should these be 
billable? One line of rationalization might be that 
that if a technique is revealed to produce positive 
outcomes (even in the absence of demonstrated specific, 
underlying mechanisms for effect), then it is billable 
(i.e. - what I call the “valued ends justification”). 
Another is that if (even a putative) mechanism is shown 
(as is the case, at least in part, for placebo) then this 
supports or “confirms” the “reality” of the technique 
as scientifically valid, and thus, a billable intervention 
(i.e.- the “mechanistic justification”). Lastly, the 
mere fact that a clinician must devote x amount of 
time to rendering said intervention may be used to 
justify incurring costs (i.e., the “professional services” 
justification).  Each may be sustainable on some level, 
and as history has shown, there have been ample 
instances of techniques being rendered and patients 
billed, without (partial, complete and/or correct) 
understanding of underlying mechanism (e.g.- aspirin, 
electroshock therapy, lithium, etc.), or even definitive 
therapeutic benefit gained. Thus, if it is determined 
that placebo may be employed as a (formal) treatment 
modality, it will then become necessary to establish 
not only particular indications for placebo-inducing 
methods, but also billing requirements and treatment 
codification for use in practice. 
Tools-to-Theory-to-Practice
Incentives of the federal Brain Research through Advancing Innovative Neurotechnologies (BRAIN) 
initiative, to develop and employ new approaches 
in neuroimaging, neurogenomics and biomarker 
identification and analysis that are specifically oriented 
toward and employable in translation of research to 
practice will enable more accurate evaluation of if, 
how, and in whom certain interventions are effective, 
which can fortify a useful corpus of “medicine-based 
evidence” (www.whitehouse.gov/BRAIN; Boswell and 
Giordano, 2009). Such evidence will be important 
to guide both clinical practice and the economics of 
patient care, particularly given recent calls for, and 
developments in personalized and precision medicine 
(see: www.whitehouse.gov/precision-medicine).  But 
caution is warranted when discerning what types and 
levels of evidence have meaning and value, and what 
social and economic implications, effects and practices 
are derived from these findings (Giordano, 2014; 2010). 
 In support of Crane I agree that mechanism and 
outcomes’ studies may strengthen consideration of using 
placebo as and in clinical practice. As consistent with 
Bok (1974), I also claim that using placebo in the clinical 
setting may be acceptable if 1) there is an established 
clinician-patient relationship; 2) a diagnosis supports 
the viability of such intervention and does not mandate 
other treatment(s); 3) the patient requires and requests 
some form of intervention; 4) it does not interfere with 
(other) diagnostic and therapeutic interventions, 5) it 
does not incur costs beyond the minimal fees required 
for the attendance of the treating clinician, and 6) 
other treatments have not been effective.  By definition, 
placebo responses are those that evoke a positive effect 
in the patient.  By definition, medicine is a humanistic 
endeavor of curing, healing, and caring. In conclusion, I 
argue that the former may prove to be important to–and 
useful in–the latter. But as with any clinical intervention, 
ongoing research, education, ethico-legal insight and 
responsibility, and practical wisdom will be essential to 
guiding its viability, value, and use in practice. 
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